New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
13th September 2022
UK - Scotland: The Scottish Medicines Consortium announced yesterday that Sativex was accepted for use within NHSScotland as treatment for relieving symptoms in adults with multiple sclerosis who have not responded adequately to other treatments.
27th May 2022
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.